Unknown

Dataset Information

0

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.


ABSTRACT: KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule inhibitor compound 0375-0604 targeting KRAS by using molecular docking based virtual screening approach. Compound 0375-0604 had a good binding affinity to KRAS in vitro and exhibited cytotoxicity in oncogenic KRAS expressing NSCLC cell lines. Further mechanism study showed that compound 0375-0604 can block the formation of the complex of guanosine triphosphate (GTP) and KRAS in vitro. In addition, compound 0375-0604 inhibited KRAS downstream signaling pathway RAF/MEK/ERK and RAF/PI3K/AKT. Finally, we also found that this compound can inhibit the cell growth through G2/M cell cycle arrest and induce apoptosis on the NSCLC cell lines harboring KRAS mutation. Therefore, compound 0375-0604 may be considered as a potential KRAS inhibitor for treatment of NSCLC carrying KRAS oncogene.

SUBMITTER: Xie C 

PROVIDER: S-EPMC5694459 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.

Xie Chun C   Li Ying Y   Li Lan-Lan LL   Fan Xing-Xing XX   Wang Yu-Wei YW   Wei Chun-Li CL   Liu Liang L   Leung Elaine Lai-Han EL   Yao Xiao-Jun XJ  

Frontiers in pharmacology 20171114


KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogenic driver with mutations in 30% of non-small cell lung cancer (NSCLC). However, there is no effective clinical drug even though it has been identified as an oncogene for 30 years. In this study, we identified a small molecule inhibitor compound 0375-0604 targeting KRAS by using molecular docking based virtual screening approach. Compound 0375-0604 had a good binding affinity to KRAS <i>in vitro</i> and exhibited cytotoxicit  ...[more]

Similar Datasets

| S-EPMC6071718 | biostudies-literature
| S-EPMC8784727 | biostudies-literature
| S-EPMC8656763 | biostudies-literature
| S-EPMC5153335 | biostudies-literature
| S-EPMC4689161 | biostudies-literature
| S-EPMC8733471 | biostudies-literature
| S-EPMC4697681 | biostudies-literature
| S-EPMC7352653 | biostudies-literature
| S-EPMC6071735 | biostudies-literature
| S-EPMC3822432 | biostudies-literature